Registry of Patients Treated With Systemic Mold-Active Triazoles

Astellas

Status

Completed

Conditions

Invasive Fungal Infection

Treatments

Drug: Voriconazole

Drug: Isavuconazonium sulfate

Drug: Posaconazole

Study type

Observational

Funder types

Industry

Identifiers

NCT03066011

9766-MA-3034

Details and patient eligibility

About

The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).

Enrollment

2,015 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients taking one of the following target drugs at the time of enrollment: isavuconazonium sulfate (ISAV), voriconazole (VORI), posaconazole (POSA).

Exclusion criteria

Currently enrolled in any clinical trial with an investigational antifungal agent. Individuals who subsequently enroll in an investigational antifungal study will be discontinued and data collected up to the time of investigational product will be evaluable.
Patients who died before entering the study.
Patients who previously participated in this registry.